Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 389
- Registration Number
- NCT04154956
- Locations
- 🇮🇳
Investigational Site Number : 3560011, Trivandrum, India
🇺🇸National Jewish Health Site Number : 8400033, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists South Division Site Number : 8400020, Fort Myers, Florida, United States
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
- Conditions
- Fabry Disease
- Interventions
- Drug: agalsidase beta (GZ419828)
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT04143958
A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)
- Conditions
- Sphingomyelin Lipidosis
- Interventions
- Procedure: Investigational Procedures
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT04106544
- Locations
- 🇧🇷
Investigational Site Number :0760001, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇷Investigational Site Number :0320002, Caba, Argentina
🇹🇷Investigational Site Number :7920001, Izmir, Turkey
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine, 300 U/mlDrug: Insulin degludec, 100U/ml
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 343
- Registration Number
- NCT04075513
- Locations
- 🇬🇧
Investigational site United Kingdom, United Kingdom, United Kingdom
🇭🇺Investigational site Hungary, Hungary, Hungary
🇺🇸United States, Dallas, Texas, United States
A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Drug: Plasma exchange (PE)Drug: Corticosteroid treatment (Methylprednisolone or prednisolone)Drug: Immunosuppressive treatment (eg, rituximab)
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 21
- Registration Number
- NCT04074187
- Locations
- 🇯🇵
Investigational Site Number 3920009, Iruma-Gun, Japan
🇯🇵Investigational Site Number 3920007, Kashihara-Shi, Japan
🇯🇵Investigational Site Number 3920003, Kurashiki-Shi, Japan
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 367
- Registration Number
- NCT04059484
- Locations
- 🇺🇦
Investigational Site Number : 8040001, Kryvyi Rih, Ukraine
🇬🇷Investigational Site Number : 3000004, Thessaloniki, Greece
🇧🇷Hospital de Clinicas de Porto Alegre - HCPA Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil
Acne Vulgaris Related Microbiology and Serology
- Conditions
- Acne Vulgaris
- Interventions
- Diagnostic Test: Study of humoral immunity
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 120
- Registration Number
- NCT04056598
- Locations
- 🇺🇸
Clinical Research Associates of Tidewater, Norfolk, Virginia, United States
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- Device: Investigational injector device
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 56
- Registration Number
- NCT04045795
- Locations
- 🇦🇺
Investigational Site Number : 0360004, Fitzroy, Victoria, Australia
🇺🇸~Banner MD Anderson Cancer Center Site Number : 8400005, Gilbert, Arizona, United States
🇯🇵Investigational Site Number : 3920002, Okayama-shi, Okayama, Japan
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 188
- Registration Number
- NCT04033367
- Locations
- 🇮🇹
Investigational Site Number :3800001, Pisa, Italy
🇪🇸Investigational Site Number :7240003, Manises, Valencia, Spain
🇮🇹Investigational Site Number :3800002, Roma, Italy
Efficacy and Safety of Teicoplanin in CDAD
- Conditions
- Clostridium Difficile Infection-associated Diarrhea and Colitis
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT04003818
- Locations
- 🇨🇳
investigational site CHINA, China, China